Scientific progress depends on the expertise,
reagents and technologies behind every experiment.
Fortis was established in 2020 to create a more unified and scalable approach to supporting modern research and development.
7
Global brands unified
6
NA manufacturing & R&D sites · 3 ISO 13485
30,000+
Citations in publications
Together, Fortis companies provide capabilities across
so you can work with greater continuity across complex scientific workflows.
1,100+
Customers globally
75+
Distributors · 65 countries
Work that once required multiple suppliers can now move forward with one partner: stronger technical alignment, a more stable supply chain, and support across discovery, translational research, and advanced biologics development.
Acquired by Fortis Oct 2020
For more than fifty years, Bethyl Laboratories has manufactured antibodies, proteins, and immunoassay kits in-house in Montgomery, Texas, tested for specificity and reproducibility across such as: flow cytometry, spatial biology, and ELISA platforms.
Founded 1972
Acquired by Fortis Feb 2021
Abcore’s VHH single-domain antibody discovery, built on phage display screening, addresses difficult and emerging targets across research, therapeutic, and diagnostic programs
Founded 2011
Acquired by Fortis Dec 2021
Arista Biologicals supplies highly characterized antibodies, antigens, and controls purpose-built for point-of-care and lateral flow diagnostics, backed by conjugation and assay development expertise across infectious disease, fertility, and toxicology testing.
Founded 1993
Acquired by Fortis March 2023
Once a target is identified, researchers need to confirm what happens when a gene is activated, silenced, or delivered into a living system. Vector Biolabs’ catalog and custom AAV and adenoviral vector design and production supply that functional step, moving a hypothesis toward a therapeutic candidate.
Founded 2004
Acquired by Fortis June 2021
As diagnostics and therapeutics moved toward smaller, more targeted mechanisms, nanoComposix added the materials science to match: engineered nanoparticles characterized for targeted delivery and enhanced diagnostic signal.
Founded 2004
Acquired by Fortis Sept 2021
Antibody and nanoparticle development both depend on the molecular biology tools underneath them: enzymes, master mixes, and recombinant proteins. Empirical Bioscience has that capability at production scale, supporting genomic and diagnostic workflows beyond what a single research lab can produce in-house.
Founded 2010
Acquired by Fortis Feb 2023
IPOC’s lyophilization expertise stabilizes molecular and immunodiagnostic reagents for global distribution, extending Fortis’ reach to labs and patients well beyond the range of a cold chain.
Founded 2008
Harness
the Power of Many
We’ve been consistently pleased by Bethyl’s
initial candidate success rate.
They are creative in their workflows, responsive to our inputs, and a great group to work with overall. We’re now engaged in multiple projects, with multiple anti-PTM clones about to be launched as formal genomic mapping reagents.
Michael-Christopher Keogh, PhD
Chief Scientific Officer, EpiCypher Inc.
Fortis trusted brands stand shoulder to shoulder, to accelerate the future of scientific progress.
Meet the Fortis Team >
